Shots:

• The collaboration builds on the March 2021 license agreement for $2.45B to develop BridgeBio’s infigratinib (FGFR inhibitor) in oncology indications
• Under the non-exclusive agreement, BridgeBio is eligible to receive a profit share on US sales along with royalties on Ex-US sales. The companies get the option to collaborate on preclinical oncology programs & will share global development responsibilities for each program
• The agreement will utilize BridgeBio’s drug discovery expertise and Helsinn’s clinical development and commercial capabilities to develop & commercialize the GPX4 program for cancer. Helsinn to get exclusive manufacturing and commercial rights to the programs

| Ref: BridgeBio | Image: LinkedIn